FDA Approves VIGABATRIN — Dr. Reddys Laboratories Inc.,

# FDA Approves Dr. Reddy's Laboratories Vigabatrin Generic, Expanding Market Competition Dr. Reddy's Laboratories Inc. has received FDA approval for its generic vigabatrin oral formulation, enabling the company to capture market share in the anticonvulsant segment as patent protections on branded versions expire. The approval is expected to increase treatment accessibility and drive down medication costs for patients requiring vigabatrin for seizure management.